The U.S. Food and Drug Administration (FDA) has approved inebilizumab as a treatment for generalized myasthenia gravis (gMG).
Marisa Wexler, MS
senior science writer
Marisa Horak joined Bionews in 2018 right after she completed her master’s degree in cellular and molecular pathology. She has dedicated her career to making scientific and medical information more accessible to people affected by rare and chronic disorders.
Education
- MS, Cellular and Molecular Pathology, University of Pittsburgh
- BS, Microbiology, Michigan State University
Professional Accomplishments
- Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways, 2019, Briefings in Bioinformatics
- Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity, 2018, Oncotarget
- Insights on processes of evolutionary tumor growth, 2016, Atlas Genet Cytogenet Oncol Haematol
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
For people with generalized myasthenia gravis (MG) in the U.S., getting a correct diagnosis is often a difficult and…
The Myasthenia Gravis Foundation of America (MGFA) has published a new resource designed to help people with myasthenia…
Note: This story was updated Nov. 26, 2025, to correct that the cladribine formulation being tested as a potential gMG…
Results from an ongoing Phase 1/2 clinical trial testing Cabaletta Bio‘s experimental cell therapy rese-cel (resecabtagene autoleucel) in adults…
Facing the daily challenges of myasthenia gravis (MG) requires more than medication: It demands diligent self-management, including careful…
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase…
A European Medicines Agency (EMA) committee recommended that the agency approve nipocalimab as an add-on treatment for generalized myasthenia…
Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis…
Treatment with the experimental injection therapy claseprubart (DNTH103) was well tolerated and appeared to ease symptoms of generalized…